<p>Y Intercept Hong Kong Ltd 在第三季度削减了对 Alkermes plc (NASDAQ:ALKS - 免费报告) 的持股比例，减少幅度为 61.7%，根据其最近向证券交易委员会提交的 13F 文件。该公司在此期间售出了 85,366 股后，持有 53,067 股该公司的股票。Y Intercept Hong Kong Ltd 在 Alkermes 的持股在最近一个季度末的价值为 1,592,000 美元。</p>
<p>其他几家大型投资者最近也对该公司的持股进行了调整。Capital Fund Management S.A. 在第二季度购买了价值约 1,142,000 美元的 Alkermes 新头寸。EcoR1 Capital LLC 在第二季度收购了价值约 14,305,000 美元的 Alkermes 新头寸。Robeco Institutional Asset Management B.V. 在第三季度将其在 Alkermes 的持股增加了 18.6%。Robeco Institutional Asset Management B.V. 目前持有 134,387 股该公司的股票，价值 4,032,000 美元，此前在此期间又购买了 21,067 股。Frazier Life Sciences Management L.P. 在第二季度将其在 Alkermes 的持股增加了 66.5%。Frazier Life Sciences Management L.P. 目前持有 1,000,647 股该公司的股票，价值 28,629,000 美元，此前在上个季度又购买了 399,518 股。最后，Magnetar Financial LLC 在第二季度购买了价值约 3,538,000 美元的 Alkermes 新头寸。机构投资者和对冲基金持有该公司 95.21% 的股票。</p>
<h2>分析师评级调整</h2>
<p>一些股票研究分析师最近对 ALKS 股票发布了报告。Piper Sandler 在 10 月 23 日的研究报告中重申了 &#34;增持&#34; 评级，并将 Alkermes 的目标价从 38.00 美元上调至 45.00 美元。德意志银行将 Alkermes 的目标价从 55.00 美元下调至 45.00 美元，并在 11 月 13 日的报告中对该股票给予了 &#34;买入&#34; 评级。Needham &amp; Company LLC 在 10 月 29 日的研究报告中将 Alkermes 的目标价从 43.00 美元上调至 44.00 美元，并给予该公司 &#34;买入&#34; 评级。Zacks Research 在 1 月 13 日的研究报告中将 Alkermes 的评级从 &#34;持有&#34; 上调至 &#34;强力买入&#34;。最后，Weiss Ratings 在 12 月 29 日的报告中重申了对 Alkermes 的 &#34;持有 (c+)&#34; 评级。有两位研究分析师给予该股票 &#34;强力买入&#34; 评级，十一位给予 &#34;买入&#34; 评级，三位给予 &#34;持有&#34; 评级。根据 MarketBeat 的数据，该公司目前的共识评级为 &#34;适度买入&#34;，共识目标价为 44.69 美元。</p>
<p><strong>查看我们关于 ALKS 的最新研究报告</strong></p>
<h2>内部人士下注</h2>
<p>在其他消息中，执行副总裁 Craig C. Hopkinson 于 1 月 8 日星期四出售了 5,000 股该公司的股票。股票以平均价格 30.00 美元出售，总交易额为 150,000.00 美元。出售后，该执行副总裁直接持有 61,740 股公司股票，价值约 1,852,200 美元。此次交易使其持股减少了 7.49%。该交易已在向 SEC 提交的文件中披露，相关文件可通过 SEC 网站访问。在过去 90 天内，内部人士出售了价值 765,060 美元的 25,748 股公司股票。内部人士持有该公司 4.40% 的股票。</p>
<h2>Alkermes 股价下跌 2.8%</h2>
<p>NASDAQ:ALKS 的股票在周五开盘时为 33.89 美元。该公司的 50 日移动平均线为 29.82 美元，200 日移动平均线为 29.38 美元。Alkermes plc 的 12 个月低点为 25.17 美元，12 个月高点为 36.45 美元。该股票的市值为 56 亿美元，市盈率为 16.78，贝塔值为 0.48。</p>
<p>Alkermes (NASDAQ:ALKS - 获取免费报告) 最近于 10 月 28 日宣布了其季度财报。该公司报告季度每股收益为 0.49 美元，超出市场共识预期的 0.41 美元，超出幅度为 0.08 美元。Alkermes 的股本回报率为 21.81%，净利润率为 22.27%。该公司在本季度的收入为 3.9419 亿美元，而市场共识预期为 3.5523 亿美元。在去年同期，该公司每股收益为 0.73 美元。Alkermes 本季度的收入同比增长 4.3%。研究分析师平均预测，Alkermes plc 本财年的每股收益将达到 1.31 美元。</p>
<h2>Alkermes 公司简介</h2>
<p>(免费报告)</p>
<p>Alkermes plc 是一家生物制药公司，专注于开发创新药物，以满足中枢神经系统 (CNS) 的未满足需求。该公司运用其专有的药物递送技术和治疗专业知识，推进对成瘾、精神分裂症、双相 I 型障碍和抑郁症的治疗。Alkermes 的产品组合包括多个商业产品和一系列旨在改善患者结果和支持长期疾病管理的研究性疗法。</p>
<p>Alkermes 的商业产品线包括多个已获批准的产品。</p>
<h2>推荐阅读</h2>
<ul>
<li>我们更看好的五只股票超过 Alkermes</li>
<li>请勿删除，立即阅读</li>
<li>新法律：国会批准数字美元的设立？</li>
<li>用这 4 个简单步骤为您的银行账户 &#34;防联储&#34;</li>
<li>一项价值数万亿的美国 &#34;出生权&#34; 诉求 - 静悄悄地激活</li>
<li>崩盘已经开始（大多数人只是还没看到）</li>
</ul>
<p><strong>想看看其他对冲基金持有的 ALKS 吗？</strong> 访问 HoldingsChannel.com 获取 Alkermes plc (NASDAQ:ALKS - 免费报告) 的最新 13F 文件和内部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUxLUw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUxLUw"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在 Alkermes 吗？</h2>
<p>在考虑 Alkermes 之前，你会想听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而阿尔凯默斯并不在名单上。</p>
<p>虽然阿尔凯默斯目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

纽交所高增长板生物技术指数 ETF - First Trust

医疗业 ETF - SPDR

标普全球医疗股指数 ETF - iShares

<p>Y Intercept Hong Kong Ltd 在第三季度将其在 Alkermes plc 的持股减少了 61.7%，目前持有 53,067 股，价值 159 万美元。其他投资者也调整了他们的持仓，进行了显著的新投资和增持。分析师对 Alkermes 的评级褒贬不一，普遍评级为 “适度买入”，目标价为 44.69 美元。Alkermes 的股票开盘价为 33.89 美元，下跌 2.8%，市值为 56 亿美元。该公司报告第三季度每股收益为 0.49 美元，超出预期，收入为 3.9419 亿美元，同比增长 4.3%</p>

<p>Y Intercept Hong Kong Ltd trimmed its position in shares of Alkermes plc (NASDAQ:ALKS - Free Report) by 61.7% in the third quarter, according to its most recent 13F filing with the Securities &amp; Exchange Commission. The firm owned 53,067 shares of the company's stock after selling 85,366 shares during the period. Y Intercept Hong Kong Ltd's holdings in Alkermes were worth $1,592,000 at the end of the most recent quarter.</p>
<div class="lb-trans"><p>Y Intercept Hong Kong Ltd 在第三季度削减了对 Alkermes plc (NASDAQ:ALKS - 免费报告) 的持股比例，减少幅度为 61.7%，根据其最近向证券交易委员会提交的 13F 文件。该公司在此期间售出了 85,366 股后，持有 53,067 股该公司的股票。Y Intercept Hong Kong Ltd 在 Alkermes 的持股在最近一个季度末的价值为 1,592,000 美元。</p>
</div><p>Several other large investors also recently made changes to their positions in the company. Capital Fund Management S.A. bought a new position in Alkermes in the second quarter valued at approximately $1,142,000. EcoR1 Capital LLC acquired a new position in shares of Alkermes in the 2nd quarter valued at approximately $14,305,000. Robeco Institutional Asset Management B.V. boosted its holdings in shares of Alkermes by 18.6% in the third quarter. Robeco Institutional Asset Management B.V. now owns 134,387 shares of the company's stock valued at $4,032,000 after buying an additional 21,067 shares during the period. Frazier Life Sciences Management L.P. increased its holdings in Alkermes by 66.5% during the 2nd quarter. Frazier Life Sciences Management L.P. now owns 1,000,647 shares of the company's stock worth $28,629,000 after purchasing an additional 399,518 shares in the last quarter. Finally, Magnetar Financial LLC bought a new position in shares of Alkermes during the second quarter worth about $3,538,000. Institutional investors and hedge funds own 95.21% of the company's stock.</p>
<div class="lb-trans"><p>其他几家大型投资者最近也对该公司的持股进行了调整。Capital Fund Management S.A. 在第二季度购买了价值约 1,142,000 美元的 Alkermes 新头寸。EcoR1 Capital LLC 在第二季度收购了价值约 14,305,000 美元的 Alkermes 新头寸。Robeco Institutional Asset Management B.V. 在第三季度将其在 Alkermes 的持股增加了 18.6%。Robeco Institutional Asset Management B.V. 目前持有 134,387 股该公司的股票，价值 4,032,000 美元，此前在此期间又购买了 21,067 股。Frazier Life Sciences Management L.P. 在第二季度将其在 Alkermes 的持股增加了 66.5%。Frazier Life Sciences Management L.P. 目前持有 1,000,647 股该公司的股票，价值 28,629,000 美元，此前在上个季度又购买了 399,518 股。最后，Magnetar Financial LLC 在第二季度购买了价值约 3,538,000 美元的 Alkermes 新头寸。机构投资者和对冲基金持有该公司 95.21% 的股票。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师评级调整</h2>
</div><p>A number of equities research analysts have recently issued reports on ALKS shares. Piper Sandler reiterated an &#34;overweight&#34; rating and set a $45.00 price objective (up previously from $38.00) on shares of Alkermes in a research note on Thursday, October 23rd. Deutsche Bank Aktiengesellschaft lowered their target price on shares of Alkermes from $55.00 to $45.00 and set a &#34;buy&#34; rating on the stock in a report on Thursday, November 13th. Needham &amp; Company LLC increased their price target on shares of Alkermes from $43.00 to $44.00 and gave the company a &#34;buy&#34; rating in a research note on Wednesday, October 29th. Zacks Research upgraded shares of Alkermes from a &#34;hold&#34; rating to a &#34;strong-buy&#34; rating in a research note on Tuesday, January 13th. Finally, Weiss Ratings reiterated a &#34;hold (c+)&#34; rating on shares of Alkermes in a report on Monday, December 29th. Two research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and three have given a Hold rating to the stock. According to MarketBeat, the company presently has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $44.69.</p>
<div class="lb-trans"><p>一些股票研究分析师最近对 ALKS 股票发布了报告。Piper Sandler 在 10 月 23 日的研究报告中重申了 &#34;增持&#34; 评级，并将 Alkermes 的目标价从 38.00 美元上调至 45.00 美元。德意志银行将 Alkermes 的目标价从 55.00 美元下调至 45.00 美元，并在 11 月 13 日的报告中对该股票给予了 &#34;买入&#34; 评级。Needham &amp; Company LLC 在 10 月 29 日的研究报告中将 Alkermes 的目标价从 43.00 美元上调至 44.00 美元，并给予该公司 &#34;买入&#34; 评级。Zacks Research 在 1 月 13 日的研究报告中将 Alkermes 的评级从 &#34;持有&#34; 上调至 &#34;强力买入&#34;。最后，Weiss Ratings 在 12 月 29 日的报告中重申了对 Alkermes 的 &#34;持有 (c+)&#34; 评级。有两位研究分析师给予该股票 &#34;强力买入&#34; 评级，十一位给予 &#34;买入&#34; 评级，三位给予 &#34;持有&#34; 评级。根据 MarketBeat 的数据，该公司目前的共识评级为 &#34;适度买入&#34;，共识目标价为 44.69 美元。</p>
</div><p><strong>Check Out Our Latest Research Report on ALKS</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 ALKS 的最新研究报告</strong></p>
</div><h2>Insiders Place Their Bets</h2>
<div class="lb-trans"><h2>内部人士下注</h2>
</div><p>In other news, EVP Craig C. Hopkinson sold 5,000 shares of the business's stock in a transaction dated Thursday, January 8th. The stock was sold at an average price of $30.00, for a total transaction of $150,000.00. Following the sale, the executive vice president directly owned 61,740 shares in the company, valued at approximately $1,852,200. The trade was a 7.49% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. In the last 90 days, insiders sold 25,748 shares of company stock worth $765,060. Insiders own 4.40% of the company's stock.</p>
<div class="lb-trans"><p>在其他消息中，执行副总裁 Craig C. Hopkinson 于 1 月 8 日星期四出售了 5,000 股该公司的股票。股票以平均价格 30.00 美元出售，总交易额为 150,000.00 美元。出售后，该执行副总裁直接持有 61,740 股公司股票，价值约 1,852,200 美元。此次交易使其持股减少了 7.49%。该交易已在向 SEC 提交的文件中披露，相关文件可通过 SEC 网站访问。在过去 90 天内，内部人士出售了价值 765,060 美元的 25,748 股公司股票。内部人士持有该公司 4.40% 的股票。</p>
</div><h2>Alkermes Trading Down 2.8%</h2>
<div class="lb-trans"><h2>Alkermes 股价下跌 2.8%</h2>
</div><p>Shares of NASDAQ:ALKS opened at $33.89 on Friday. The firm has a 50 day moving average of $29.82 and a 200-day moving average of $29.38. Alkermes plc has a 12 month low of $25.17 and a 12 month high of $36.45. The stock has a market capitalization of $5.60 billion, a PE ratio of 16.78 and a beta of 0.48.</p>
<div class="lb-trans"><p>NASDAQ:ALKS 的股票在周五开盘时为 33.89 美元。该公司的 50 日移动平均线为 29.82 美元，200 日移动平均线为 29.38 美元。Alkermes plc 的 12 个月低点为 25.17 美元，12 个月高点为 36.45 美元。该股票的市值为 56 亿美元，市盈率为 16.78，贝塔值为 0.48。</p>
</div><p>Alkermes (NASDAQ:ALKS - Get Free Report) last announced its quarterly earnings data on Tuesday, October 28th. The company reported $0.49 earnings per share for the quarter, topping the consensus estimate of $0.41 by $0.08. Alkermes had a return on equity of 21.81% and a net margin of 22.27%.The business had revenue of $394.19 million during the quarter, compared to the consensus estimate of $355.23 million. During the same period in the prior year, the company earned $0.73 EPS. Alkermes's revenue for the quarter was up 4.3% on a year-over-year basis. On average, research analysts predict that Alkermes plc will post 1.31 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Alkermes (NASDAQ:ALKS - 获取免费报告) 最近于 10 月 28 日宣布了其季度财报。该公司报告季度每股收益为 0.49 美元，超出市场共识预期的 0.41 美元，超出幅度为 0.08 美元。Alkermes 的股本回报率为 21.81%，净利润率为 22.27%。该公司在本季度的收入为 3.9419 亿美元，而市场共识预期为 3.5523 亿美元。在去年同期，该公司每股收益为 0.73 美元。Alkermes 本季度的收入同比增长 4.3%。研究分析师平均预测，Alkermes plc 本财年的每股收益将达到 1.31 美元。</p>
</div><h2>Alkermes Company Profile</h2>
<div class="lb-trans"><h2>Alkermes 公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>(免费报告)</p>
</div><p>Alkermes plc is a biopharmaceutical company focused on developing innovative medicines to address unmet needs in the central nervous system (CNS). The company applies its proprietary drug delivery technologies and therapeutic expertise to advance treatments for addiction, schizophrenia, bipolar I disorder and depression. Alkermes' portfolio includes both commercial products and a pipeline of investigational therapies designed to improve patient outcomes and support long-term disease management.</p>
<div class="lb-trans"><p>Alkermes plc 是一家生物制药公司，专注于开发创新药物，以满足中枢神经系统 (CNS) 的未满足需求。该公司运用其专有的药物递送技术和治疗专业知识，推进对成瘾、精神分裂症、双相 I 型障碍和抑郁症的治疗。Alkermes 的产品组合包括多个商业产品和一系列旨在改善患者结果和支持长期疾病管理的研究性疗法。</p>
</div><p>Alkermes' commercial franchise features several approved products.</p>
<div class="lb-trans"><p>Alkermes 的商业产品线包括多个已获批准的产品。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推荐阅读</h2>
</div><ul>
<li>Five stocks we like better than Alkermes</li>
<li>Do not delete, read immediately</li>
<li>NEW LAW: Congress Approves Setup For Digital Dollar?</li>
<li>“Fed Proof” Your Bank Account with THESE 4 Simple Steps</li>
<li>A U.S. “birthright” claim worth trillions - activated quietly</li>
<li>The Crash Has Already Started (Most Just Don’t See It Yet)</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票超过 Alkermes</li>
<li>请勿删除，立即阅读</li>
<li>新法律：国会批准数字美元的设立？</li>
<li>用这 4 个简单步骤为您的银行账户 &#34;防联储&#34;</li>
<li>一项价值数万亿的美国 &#34;出生权&#34; 诉求 - 静悄悄地激活</li>
<li>崩盘已经开始（大多数人只是还没看到）</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding ALKS?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alkermes plc (NASDAQ:ALKS - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他对冲基金持有的 ALKS 吗？</strong> 访问 HoldingsChannel.com 获取 Alkermes plc (NASDAQ:ALKS - 免费报告) 的最新 13F 文件和内部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUxLUw" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=ALKS"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Alkermes Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Alkermes 吗？</h2>
</div><p>Before you consider Alkermes, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Alkermes 之前，你会想听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alkermes wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而阿尔凯默斯并不在名单上。</p>
</div><p>While Alkermes currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然阿尔凯默斯目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Alkermes plc $ALKS Shares Sold by Y Intercept Hong Kong Ltd

Market Beat

医疗业 ETF - Vanguard

美国制药 ETF - iShares

生物科技 ETF - VanEck Vectors

2 倍做多纳斯达克生物技术 ETF - ProShares

标普生物技术 3 倍做空 - Direxion

基因改革 ETF - ARK

纳斯达克生物科技指数 ETF - iShares Nasdaq

医药突破 ETF - ALPS

动态生物技术与基因组 ETF - Invesco

标普生物技术 ETF - SPDR

阿尔凯默斯

Y Intercept Hong Kong Ltd 出售了阿尔凯默斯公司 $ALKS 的股票